Literature DB >> 7488438

A randomised double-blind placebo controlled clinical trial assessing the tolerability and efficacy of glutathione as an adjuvant to escalating doses of cisplatin in the treatment of advanced ovarian cancer.

F X Parnis, R E Coleman, P G Harper, D Pickering, C Topham, J R Whittington, M Tedeschi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7488438     DOI： 10.1016/0959-8049(95)00310-f

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  5 in total

Review 1.  Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy.

Authors:  M Links; C Lewis
Journal:  Drugs       Date:  1999-03       Impact factor: 9.546

Review 2.  Systematic review: generating evidence-based guidelines on the concurrent use of dietary antioxidants and chemotherapy or radiotherapy.

Authors:  Akiko Nakayama; Karen P Alladin; Obianuju Igbokwe; Jeffrey D White
Journal:  Cancer Invest       Date:  2011-12       Impact factor: 2.176

Review 3.  Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies.

Authors:  Allyson J Ocean; Linda T Vahdat
Journal:  Support Care Cancer       Date:  2004-09       Impact factor: 3.603

Review 4.  The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects.

Authors:  G A Hospers; E A Eisenhauer; E G de Vries
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

Review 5.  Antioxidants as precision weapons in war against cancer chemotherapy induced toxicity - Exploring the armoury of obscurity.

Authors:  Kanchanlata Singh; Mustansir Bhori; Yasar Arfat Kasu; Ganapathi Bhat; Thankamani Marar
Journal:  Saudi Pharm J       Date:  2017-12-19       Impact factor: 4.330
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.